AKRO - Akero Therapeutics, Inc. Stock Price and Quote

AKRO | Akero Therapeutics, Inc. | [NASD]

Index	-	P/E	-	EPS (ttm)	-2.74	Insider Own	2.10%	Shs Outstand	46.94M	Perf Week	-1.89%
Market Cap	2.42B	Forward P/E	-	EPS next Y	-3.31	Insider Trans	-54.22%	Shs Float	42.37M	Perf Month	2.54%
Income	-111.80M	PEG	-	EPS next Q	-0.62	Inst Own	108.40%	Short Float / Ratio	10.97% / 6.95	Perf Quarter	1.84%
Sales	-	P/S	-	EPS this Y	0.70%	Inst Trans	20.36%	Short Interest	4.65M	Perf Half Y	-1.43%
Book/sh	6.53	P/B	6.85	EPS next Y	-20.40%	ROA	-35.20%	Target Price	59.14	Perf Year	446.94%
Cash/sh	6.33	P/C	7.06	EPS next 5Y	-14.60%	ROE	-39.80%	52W Range	7.52 - 54.88	Perf YTD	-18.36%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-18.48%	Beta	-0.92
Dividend %	-	Quick Ratio	20.80	Sales past 5Y	-	Gross Margin	-	52W Low	494.95%	ATR	2.17
Employees	41	Current Ratio	20.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.63	Volatility	5.25% 4.92%
Optionable	Yes	Debt/Eq	0.08	EPS Q/Q	26.00%	Profit Margin	-	Rel Volume	0.50	Prev Close	43.81
Shortable	Yes	LT Debt/Eq	0.08	Earnings	-	Payout	-	Avg Volume	668.94K	Price	44.74
Recom	1.70	SMA20	-1.92%	SMA50	6.32%	SMA200	15.04%	Volume	333,329	Change	2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
May-24-23 08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-23-23 09:55AM	How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22% (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
May-16-23 06:53PM	Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:33AM	Loading…
06:33AM	We're Interested To See How Akero Therapeutics (NASDAQ:AKRO) Uses Its Cash Hoard To Grow (Simply Wall St.)
May-15-23 07:00AM	Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-10-23 08:50AM	Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going (Zacks)
May-04-23 09:21AM	Why Earnings Season Could Be Great for Akero Therapeutics (AKRO) (Zacks)
06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
Apr-18-23 09:55AM	Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-29-23 04:01PM	Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH (GlobeNewswire) +5.17%
Mar-22-23 04:09PM	Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up (Investor's Business Daily)
09:14AM	89bio Rockets 30% And Akero Dives On A Scorching Battle In Liver Disease (Investor's Business Daily)
Mar-17-23 07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
08:00AM	Loading…
Jan-10-23 08:00AM	Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy (GlobeNewswire)
Jan-04-23 08:00AM	Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -10.10%
Dec-22-22 07:44AM	Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program (Benzinga) +6.09%
Dec-21-22 04:01PM	Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones (GlobeNewswire) +7.94%
Dec-20-22 11:15AM	Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study (Zacks) +7.85%
Dec-08-22 07:00AM	Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH (GlobeNewswire)
Nov-13-22 07:46AM	Akero Therapeutics, Inc.'s (NASDAQ:AKRO) large institutional owners must be happy as stock continues to impress, up 5.6% over the past week (Simply Wall St.)
Nov-10-22 04:05PM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Nov-07-22 09:40AM	Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year? (Zacks)
07:30AM	Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLDs The Liver Meeting® 2022 (GlobeNewswire)
Nov-04-22 07:00AM	Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.05%
Nov-03-22 06:53PM	10 Best Small-Cap Stocks To Buy Now (Insider Monkey)
Nov-02-22 11:14AM	Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +5.59%
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
09:40AM	Loading…
09:40AM	Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year? (Zacks)
Oct-11-22 08:56PM	Why J.P. Morgan Believes These 3 Stocks Are Attractive in the Current Market (TipRanks)
04:01PM	Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference (GlobeNewswire)
Oct-05-22 09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-23-22 06:35PM	Purple Innovation and Edgewise Therapeutics Stock See Action From Activist Investors (Barrons.com)
Sep-19-22 04:01PM	Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-14-22 08:07PM	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:35PM	Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More (Zacks)
02:50PM	Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
01:35PM	Akero Therapeutics (AKRO) Up on Positive Data from NASH Study (Zacks)
10:27AM	Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise (Benzinga)
Sep-13-22 04:31PM	Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment (Investor's Business Daily) +136.76%
04:01PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:05AM	'Fatty liver' drug trial data sends Peninsula biotech's stock soaring more than 100% (American City Business Journals)
11:04AM	Why Akero Therapeutics Stock Is on Fire Today (Motley Fool)
09:10AM	Peloton's Shake-Up Continues, but This Tiny Stock Doubled Early Tuesday (Motley Fool)
08:27AM	Akero's experimental NASH drug meets the primary endpoint in a clinical trial (MarketWatch)
07:49AM	Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study (Benzinga)
06:00AM	In Akero Therapeutics Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks (GlobeNewswire)
Sep-08-22 04:01PM	Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH (GlobeNewswire) +10.76%
Aug-25-22 11:53AM	Akero Therapeutics (AKRO) Up on Positive NASH Study Data (Zacks)
Aug-24-22 10:28AM	Akero Lead Candidate Improves Fibrosis In Cirrhotic NASH Patients (Benzinga) +9.38%
08:00AM	Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment (GlobeNewswire)
Aug-04-22 04:05PM	Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.88%
Jun-27-22 07:00AM	Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis (GlobeNewswire)
Jun-16-22 09:22AM	Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma (Benzinga) +22.00%
07:00AM	Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million (GlobeNewswire)
Jun-13-22 08:00AM	Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH (GlobeNewswire) -5.62%
Jun-01-22 04:05PM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -7.41%
May-06-22 07:00AM	Akero Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-02-22 07:30AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in May (GlobeNewswire) +7.24%
Mar-07-22 04:13AM	We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely (Simply Wall St.)
Feb-25-22 07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-08-22 08:00AM	Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients (GlobeNewswire)
Jan-14-22 09:40AM	Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-04-22 04:05PM	Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-21 05:28PM	Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-17-21 10:07AM	Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet (Zacks)
Nov-12-21 08:01AM	Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 04:15PM	Akero Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-21 10:03AM	Akero Therapeutics NASH Treatment Gets Fast Track Designation; Shares Rise (SmarterAnalyst)
Oct-19-21 04:15PM	Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH (GlobeNewswire)
Oct-05-21 08:00AM	Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference (GlobeNewswire)
Sep-08-21 06:21AM	Here's Why We're Not Too Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Situation (Simply Wall St.)
Sep-07-21 08:00AM	Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference (GlobeNewswire)
Aug-13-21 07:00AM	Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-14-21 08:00AM	Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors (GlobeNewswire) -5.24%
Jul-08-21 01:24PM	Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment (Benzinga)
11:10AM	Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment (GlobeNewswire)
Jun-25-21 11:30AM	Akero Therapeutics Presents at the American Diabetes Associations 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients (GlobeNewswire)
Jun-21-21 11:33AM	Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients (Benzinga)
08:00AM	Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH (GlobeNewswire)
Jun-09-21 10:03AM	Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel (Zacks)
09:06AM	Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions? (Zacks)
Jun-01-21 08:00AM	Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress (GlobeNewswire)
May-28-21 04:05PM	Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
10:09AM	Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis (Zacks)
May-13-21 07:00AM	Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Apr-26-21 08:00AM	Akero Therapeutics Appoints Yuan Xu to its Board of Directors (GlobeNewswire)
Mar-23-21 08:00AM	Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY) (GlobeNewswire)
Mar-22-21 04:01PM	Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C (GlobeNewswire) +7.75%
06:30AM	Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients (GlobeNewswire)
Mar-16-21 08:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results (GlobeNewswire)
Mar-11-21 11:40PM	We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely (Simply Wall St.)
Feb-24-21 08:30AM	Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH (PR Newswire)
Feb-23-21 04:05PM	Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March (PR Newswire)
Jan-04-21 04:05PM	Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-20 10:07PM	Is AKRO A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 04:05PM	Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference (Business Wire)

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Graham G. Walmsley	Director	Sep 19	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Graham G. Walmsley	Director	May 19	Buy	42.00	120,000	5,040,000	520,000	May 23 09:55 PM
Cheng Andrew	President & CEO	May 01	Option Exercise	0.61	25,000	15,375	434,293	May 03 08:28 PM
Cheng Andrew	President & CEO	May 01	Sale	45.07	25,000	1,126,860	409,293	May 03 08:28 PM
Cheng Andrew	President & CEO	Apr 18	Option Exercise	0.61	40,000	24,600	409,293	May 03 08:28 PM
Cheng Andrew	President & CEO	Apr 03	Option Exercise	0.61	25,000	15,375	394,293	Apr 05 04:55 PM
Cheng Andrew	President & CEO	Apr 03	Sale	37.94	25,000	948,576	369,293	Apr 05 04:55 PM
Cheng Andrew	President & CEO	Mar 01	Option Exercise	0.61	25,000	15,375	395,999	Mar 03 04:21 PM
Cheng Andrew	President & CEO	Mar 01	Sale	46.65	25,000	1,166,338	370,999	Mar 03 04:21 PM
Cheng Andrew	President & CEO	Feb 01	Option Exercise	0.61	25,000	15,375	395,999	Feb 03 05:25 PM
Cheng Andrew	President & CEO	Feb 01	Sale	49.06	25,000	1,226,395	370,999	Feb 03 05:25 PM
Yale Catriona	Chief Development Officer	Jan 13	Sale	50.53	5,000	252,651	81,268	Jan 18 05:30 PM
Cheng Andrew	President & CEO	Jan 03	Option Exercise	0.61	25,000	15,375	395,999	Jan 05 06:46 PM
Young Jonathan	Chief Operating Officer	Jan 03	Option Exercise	0.61	8,777	5,398	193,688	Jan 05 05:56 PM
Cheng Andrew	President & CEO	Jan 03	Sale	51.27	25,000	1,281,751	370,999	Jan 05 06:46 PM
Young Jonathan	Chief Operating Officer	Jan 03	Sale	54.64	8,777	479,560	184,911	Jan 05 05:56 PM
Rolph Timothy	Chief Scientific Officer	Dec 29	Option Exercise	28.35	7,816	221,584	210,848	Dec 30 04:26 PM
Rolph Timothy	Chief Scientific Officer	Dec 29	Sale	51.05	20,316	1,037,119	190,532	Dec 30 04:26 PM
Rolph Timothy	Chief Scientific Officer	Dec 28	Option Exercise	28.35	1,700	48,195	204,732	Dec 30 04:26 PM
White William Richard	Chief Financial Officer	Dec 28	Option Exercise	7.01	999	7,002	24,623	Dec 29 05:41 PM
Rolph Timothy	Chief Scientific Officer	Dec 28	Sale	50.00	1,700	85,006	203,032	Dec 30 04:26 PM
White William Richard	Chief Financial Officer	Dec 28	Sale	49.76	999	49,714	23,624	Dec 29 05:41 PM
White William Richard	Chief Financial Officer	Dec 27	Option Exercise	7.01	19,001	133,178	42,625	Dec 29 05:41 PM
Young Jonathan	Chief Operating Officer	Dec 27	Option Exercise	6.03	12,500	75,352	194,949	Dec 28 06:30 PM
White William Richard	Chief Financial Officer	Dec 27	Sale	49.77	19,001	945,609	23,624	Dec 29 05:41 PM
Young Jonathan	Chief Operating Officer	Dec 27	Sale	49.57	12,500	619,609	182,449	Dec 28 06:30 PM
Cheng Andrew	President & CEO	Dec 16	Option Exercise	0.61	8,500	5,228	370,999	Dec 20 07:46 PM
Yale Catriona	Chief Development Officer	Dec 12	Sale	43.23	5,000	216,137	86,268	Dec 13 08:24 PM
Cheng Andrew	President & CEO	Dec 01	Option Exercise	0.61	10,000	6,150	320,148	Dec 02 05:52 PM
Skorpios Trust	Former 10% owner	Dec 01	Sale	43.50	1,636,000	71,166,000	3,271,829	Dec 05 04:36 PM
Cheng Andrew	President & CEO	Dec 01	Sale	46.07	10,000	460,700	310,148	Dec 02 05:52 PM
Harrison Seth Loring	Director	Nov 30	Sale	46.94	12,030	564,673	148,063	Dec 02 05:48 PM
Harrison Seth Loring	Director	Nov 30	Sale	46.94	11,101	521,067	136,301	Dec 02 05:48 PM
Rolph Timothy	Chief Scientific Officer	Nov 16	Sale	45.47	3,947	179,464	183,837	Nov 16 07:15 PM
Rolph Timothy	Chief Scientific Officer	Nov 15	Sale	45.04	3,138	141,343	187,784	Nov 16 07:15 PM
Yale Catriona	Chief Development Officer	Nov 10	Sale	39.42	5,000	197,105	72,073	Nov 14 05:26 PM
Cheng Andrew	President & CEO	Nov 01	Option Exercise	0.61	10,000	6,150	320,148	Nov 02 09:52 PM
Cheng Andrew	President & CEO	Nov 01	Sale	43.42	10,000	434,183	310,148	Nov 02 09:52 PM
Harrison Seth Loring	Director	Oct 28	Sale	40.31	22,965	925,738	160,093	Nov 01 05:38 PM
Harrison Seth Loring	Director	Oct 28	Sale	40.31	21,138	852,091	147,402	Nov 01 05:38 PM
Harrison Seth Loring	Director	Oct 27	Sale	41.53	72,172	2,997,575	183,058	Oct 27 09:50 PM
Harrison Seth Loring	Director	Oct 27	Sale	41.53	66,426	2,758,920	168,540	Oct 27 09:50 PM
Harrison Seth Loring	Director	Oct 26	Sale	43.75	71,583	3,131,402	255,230	Oct 27 09:50 PM
Harrison Seth Loring	Director	Oct 26	Sale	43.75	65,885	2,882,142	234,966	Oct 27 09:50 PM
Rolph Timothy	Chief Scientific Officer	Oct 26	Sale	45.03	4,762	214,433	190,922	Oct 27 09:27 PM
Rolph Timothy	Chief Scientific Officer	Oct 25	Option Exercise	10.31	10,000	103,116	206,337	Oct 27 09:27 PM
Young Jonathan	Chief Operating Officer	Oct 25	Option Exercise	6.36	12,500	79,500	175,754	Oct 27 09:25 PM
Young Jonathan	Chief Operating Officer	Oct 25	Sale	44.72	12,500	558,944	163,254	Oct 27 09:25 PM
Rolph Timothy	Chief Scientific Officer	Oct 25	Sale	45.09	10,653	480,349	195,684	Oct 27 09:27 PM
Harrison Seth Loring	Director	Oct 25	Sale	44.92	4,906	220,359	326,813	Oct 27 09:50 PM
Harrison Seth Loring	Director	Oct 25	Sale	44.92	4,515	202,797	300,851	Oct 27 09:50 PM
White William Richard	Chief Financial Officer	Oct 13	Option Exercise	7.01	20,000	140,180	24,429	Oct 17 05:40 PM
White William Richard	Chief Financial Officer	Oct 13	Sale	39.82	20,000	796,400	4,429	Oct 17 05:40 PM
Yale Catriona	Chief Development Officer	Oct 10	Sale	37.99	5,000	189,950	77,073	Oct 12 04:59 PM
Rolph Timothy	Chief Scientific Officer	Oct 06	Option Exercise	21.09	10,000	210,900	208,837	Oct 07 06:00 PM
Rolph Timothy	Chief Scientific Officer	Oct 06	Sale	39.29	22,500	884,025	186,337	Oct 07 06:00 PM
Cheng Andrew	President & CEO	Oct 03	Option Exercise	0.61	10,000	6,150	320,148	Oct 05 08:55 AM
Cheng Andrew	President & CEO	Oct 03	Sale	33.23	10,000	332,278	310,148	Oct 05 08:55 AM
Rolph Timothy	Chief Scientific Officer	Sep 30	Option Exercise	16.43	20,000	328,589	243,837	Oct 04 08:57 PM
Rolph Timothy	Chief Scientific Officer	Sep 30	Sale	32.72	45,000	1,472,400	198,837	Oct 04 08:57 PM
White William Richard	Chief Financial Officer	Sep 13	Option Exercise	7.01	32,500	227,792	36,929	Sep 15 07:57 PM
Cheng Andrew	President & CEO	Sep 13	Option Exercise	0.61	60,000	36,900	370,148	Sep 15 07:59 PM
Cheng Andrew	President & CEO	Sep 13	Sale	27.42	60,000	1,645,444	310,148	Sep 15 07:59 PM
Yale Catriona	Chief Development Officer	Sep 13	Sale	27.48	40,000	1,099,228	82,073	Sep 15 07:59 PM
White William Richard	Chief Financial Officer	Sep 13	Sale	27.03	32,500	878,341	4,429	Sep 15 07:57 PM
Rolph Timothy	Chief Scientific Officer	Sep 13	Sale	29.18	22,500	656,550	223,837	Sep 15 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience